CORPORATE STATEMENT: Biocartis Joins COVID-19 Testing Industry Consortium of Nineteen Healthcare Community Organizations

CORPORATE STATEMENT

1 October 2020, 08:00 ET/02:00 CEST

Biocartis Joins COVID-19 Testing Industry Consortium of

Nineteen Healthcare Community Organizations

Consortium members will work together to increase opportunities to accelerate research

through enhanced collaboration and information sharing, with the ultimate goal of improving

aspects of COVID-19 testing across the globe

Mechelen, Belgium, 1 October 2020 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces to join forces with eighteen healthcare companies in a COVID-19 Testing Industry Consortium, with the aim to improve, innovate and accelerate all aspects of testing, including research, regulatory oversight, clinical implications, reliability and access.

Widespread accurate testing for SARS-CoV-2, the virus that causes COVID-19, is one critical aspect needed to limit the spread of the disease. By creating the COVID-19 Testing Industry Consortium, 19 companies from the healthcare industry have joined forces with a goal to help inform, improve, innovate and accelerate various aspects of testing, ranging from research to clinical diagnostic implications.

The consortium brings together a diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, to help provide clarity and potential solutions to COVID-19 testing challenges. To enhance the goals of the Consortium, members may:

• Share relevant expertise, materials and experiences to accelerate understanding of COVID-19.
• Analyze available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm.
• Contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the Consortium's findings.

The Consortium was organized and is led by Bristol Myers Squibb. Consortium members include:

• Alnylam Pharmaceuticals, Inc.
• ArcherDx, Inc.
• Biocartis NV
• Color
• Diaceutics, PLC
• DxTerity Diagnostics, Inc.
• Genosity, Inc.
• GlaxoSmithKline, LLC
• Hematogenix Laboratory Services
• Infinity BiologiX
• Interpace Pharma Solutions, Inc.
• Janssen Pharmaceutica, NV
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories, Inc.
• Novartis Institute for BioMedical Research
• Ortho Clinical Diagnostics, Inc.
• Syngene International Limited
• Takeda Pharmaceutical Company Limited ('Takeda')

Herman Verrelst, Chief Executive Officer of Biocartis, reacted: "We are very excited to join forces with eighteen healthcare companies to help improve and accelerate all aspects of COVID-19testing. In answer to the high market needs, although outside of our focus on oncology, Biocartis alsodeveloped aSARS-CoV-2testdetecting the virus that causes COVID-19,on its fully automated, rapid and easy to use molecular diagnostics Idylla™ platform. Joining forces with partners in these pandemic times, where the need for high quality, rapid and easy diagnostic testing for every patient is undebatable, is at the heart of our mission as a company."

"To uncover innovative ways to improve COVID-19 testing quickly during this global pandemic, it's critical that we break down silos and bring together researchers from different organizations with complementary areas of expertise," said Saurabh Saha, M.D., Ph.D., senior vice president, Translational Medicine, Bristol Myers Squibb. "This is just one of the many ways that the healthcare community is working together to help solve the COVID-19 pandemic. BMS is proud to lead this Consortium and we look forward to building upon the important work that's already been done in this space."

--- END ---

1

More information:

Biocartis:

Click hereto read more about Biocartis' response to COVID-19.

For further inquiries, please contact:

Renate Degrave, Head of Corporate Communications & Investor Relations Biocartis

e-mail	[e-mail]
tel	+32	15 631 729
mobile	+32	471 53 60 64

@Biocartis_ www.linkedin.com/Biocartis

BMS:

Click hereto read more about Bristol Myers Squibb's response to COVID-19.

For further inquiries, please contact [e-mail].

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result,real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com.Follow us on Twitter: @Biocartis_.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.comor follow us on LinkedIn,Twitter,YouTube,Facebookand Instagram.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward- looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

2